Hyperprolactinemia Unknown Status Phase 4 Trials for Aripiprazole (DB01238)

Also known as: Hyperprolactinemic disorder / Hyperprolactinaemia / Hyperprolactinemia (disorder)

IndicationStatusPhase
DBCOND0000952 (Hyperprolactinemia)Unknown Status4
clinicaltrials.gov IdentifierTitlePurposeDrugs
NCT01742390A Multicenter Study to Evaluate the Effects of Switching to Aripiprazole 12 Weeks on the Sexual Dysfunction From Risperidone or Paliperidone in Patients With Schizophrenia Spectrum Disorders or Bipolar Spectrum DisordersTreatment
NCT00541554Reversal of Antipsychotic-Induced Hyperprolactinemia, Weight Gain, Hyperglycemia and DyslipidemiaTreatment